Float Short %

8.67

Margin Of Safety %

Put/Call OI Ratio

1.34

EPS Next Q Diff

0.03

EPS Last/This Y

-1.51

EPS This/Next Y

-0.87

Price

58.47

Target Price

102.11

Analyst Recom

1.2

Performance Q

18.13

Upside

-209.3%

Beta

1.33

Ticker: PCVX

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-01-23	PCVX	52.73	0.78	0.33	6277
2026-01-26	PCVX	53.36	0.76	0.18	6456
2026-01-27	PCVX	54.33	0.77	9.18	6425
2026-01-28	PCVX	51.38	0.78	0.12	6455
2026-01-29	PCVX	52.77	0.80	0.00	6414
2026-01-30	PCVX	53.6	0.79	1.47	6429
2026-02-02	PCVX	57.45	0.79	1.77	6481
2026-02-03	PCVX	55.75	0.75	5.32	6492
2026-02-04	PCVX	55.26	0.76	0.93	6574
2026-02-05	PCVX	53.88	0.78	0.65	6627
2026-02-06	PCVX	56.12	0.80	23.17	6664
2026-02-09	PCVX	55.61	0.79	7.20	7115
2026-02-10	PCVX	54.7	0.80	0.02	7146
2026-02-11	PCVX	55.29	0.81	2.00	7123
2026-02-12	PCVX	54.89	0.81	0.67	7123
2026-02-13	PCVX	54.21	0.81	91.00	7120
2026-02-17	PCVX	53.38	0.80	1.95	7146
2026-02-18	PCVX	56.2	0.81	64.82	7177
2026-02-19	PCVX	57.32	1.34	1.22	9260
2026-02-20	PCVX	58.45	1.34	0.61	9309
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-01-23	PCVX	52.72	-42.3	-	-5.31
2026-01-26	PCVX	53.38	-42.3	-	-5.31
2026-01-27	PCVX	54.38	-42.3	-	-5.31
2026-01-28	PCVX	51.38	-42.3	-	-5.31
2026-01-29	PCVX	52.76	-42.3	-	-5.31
2026-01-30	PCVX	53.63	-42.3	-	-5.31
2026-02-02	PCVX	57.38	-46.2	-	-5.31
2026-02-03	PCVX	55.74	-42.3	-	-5.31
2026-02-04	PCVX	55.26	-47.7	-	-5.31
2026-02-05	PCVX	53.89	-47.7	-	-5.31
2026-02-06	PCVX	56.12	-47.7	-	-5.31
2026-02-09	PCVX	55.60	-47.7	-	-5.31
2026-02-10	PCVX	54.96	-47.7	-	-5.31
2026-02-11	PCVX	55.33	-47.7	-	-5.31
2026-02-12	PCVX	54.87	-47.7	-	-5.31
2026-02-13	PCVX	54.08	-47.7	-	-5.31
2026-02-17	PCVX	53.39	-47.7	-	-5.31
2026-02-18	PCVX	56.13	-47.7	-	-5.31
2026-02-19	PCVX	57.32	-47.7	-	-5.31
2026-02-20	PCVX	58.47	-47.7	-	-5.31
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-01-23	PCVX	-0.55	-3.80	9.37
2026-01-26	PCVX	-0.55	-3.77	9.37
2026-01-27	PCVX	-0.55	-3.77	9.37
2026-01-28	PCVX	-0.55	-3.77	9.52
2026-01-29	PCVX	-0.55	-3.77	9.52
2026-01-30	PCVX	-0.55	-3.77	9.52
2026-02-02	PCVX	-0.55	-3.84	9.52
2026-02-03	PCVX	-0.55	-3.84	9.52
2026-02-04	PCVX	-0.51	-3.84	9.52
2026-02-05	PCVX	-0.51	-3.84	8.78
2026-02-06	PCVX	-0.51	-3.84	8.78
2026-02-09	PCVX	-0.51	-3.93	8.78
2026-02-10	PCVX	-0.51	-3.93	8.78
2026-02-11	PCVX	-0.51	-3.93	8.68
2026-02-12	PCVX	-0.51	-3.93	8.68
2026-02-13	PCVX	-0.51	-3.93	8.68
2026-02-17	PCVX	-0.51	-0.10	8.68
2026-02-18	PCVX	-0.51	-0.10	8.68
2026-02-19	PCVX	-0.51	-0.10	8.68
2026-02-20	PCVX	-0.51	-0.10	8.67
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

-1.56

Avg. EPS Est. Current Quarter

-1.45

Avg. EPS Est. Next Quarter

-1.53

Insider Transactions

-0.51

Institutional Transactions

-0.1

Beta

1.33

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

51.7

Max Drawdown 5-Year %

-76.2

Target Price

102.11

P/E

Forward P/E

PEG

P/S

P/B

2.63

P/Free Cash Flow

EPS

-4.92

Average EPS Est. Cur. Y

-5.31

EPS Next Y. (Est.)

-6.18

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

0.77

Return on Equity vs Sector %

-51.7

Return on Equity vs Industry %

-34.3

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

Vaxcyte, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 414

Vaxcyte, Inc., a clinical-stage vaccine innovation company, develops conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent carrier-sparing investigational pneumococcal conjugate vaccine (PCV) for the prevention of invasive pneumococcal disease (IPD) in infants. The company also develops VAX-31, a 31-valent, carrier-sparing investigational PCV for the prevention of IPD in adults and children; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting the keystone pathogen responsible for periodontitis; and VAX-GI, a novel preclinical vaccine candidate for the treatment of dysentery and shigellosis, which is caused by Shigella bacteria. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.

stock quote shares PCVX – Vaxcyte, Inc. Stock Price stock today

news today PCVX – Vaxcyte, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch PCVX – Vaxcyte, Inc. yahoo finance google finance

stock history PCVX – Vaxcyte, Inc. invest stock market

stock prices PCVX premarket after hours

ticker PCVX fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: PCVX

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y